| Company Name | Announcement |
|---|---|
| Modi Naturals
Modi Naturals
[07-Jul-2026] |
Modi Naturals announced that the 52th Annual General Meeting(AGM) of the company will be held on 31 July 2026. |
| Apar Inds.
Apar Inds.
[07-Jul-2026] |
Apar Industries announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 30 July 2026. |
| Radico Khaitan
Radico Khaitan
[07-Jul-2026] |
Radico Khaitan has allotted 51,048 equity shares of Rs. 2/- each to the eligible employee(s) pursuant to exercise of stock options under the ESOP 2006 of the Company. The paid- up equity share capital of the company, post this allotment, stands 13,39,82,398 equity shares of Rs. 2/- each aggregating to Rs. 26,79,64,796/-. |
| Cholaman.Inv.&Fn
Cholaman.Inv.&Fn
[07-Jul-2026] |
Cholamandalam Investment & Fin. Co. will hold a meeting of the Board of Directors of the Company on 28 July 2026. |
| Tata Elxsi
Tata Elxsi
[07-Jul-2026] |
Tata Elxsi will hold a meeting of the Board of Directors of the Company on 14 July 2026. |
| Kotak Mah. Bank
Kotak Mah. Bank
[07-Jul-2026] |
Kotak Mahindra Bank will hold a meeting of the Board of Directors of the Company on 18 July 2026. |
| Banswara Syntex
Banswara Syntex
[07-Jul-2026] |
Banswara Syntex announced that the 50th Annual General Meeting(AGM) of the company will be held on 30 July 2026. |
| Orchid Pharma
Orchid Pharma
[07-Jul-2026] |
Orchid Pharma (Orchid) and Pharmasyntez JSC (Pharmasyntez) have entered into a licensing and supply agreement for Exblifep® (cefepime/enmetazobactam), a novel combination antibiotic for the treatment of complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gram negative bacterial pathogens, subject to regulatory approval by the Ministry of Health of the Russian Federation. </P> Exblifep is a carbapenem-sparing antibiotic developed to address the growing clinical challenge posed by ESBL-producing Gram-negative bacteria in serious hospital infections. The product is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is included in IDSA and EUCAST treatment guidelines, and is the first new chemical entity originating from an Indian pharmaceutical company to receive both approvals. </P> Under the agreement, Pharmasyntez will hold the exclusive rights to register and commercialize Exblifep in Russia, with Orchid supplying the finished dosage form. The partnership represents a potential opportunity of approximately USD 178 million over the first 10 years, reflecting the scale of unmet clinical need and the significant hospital procurement volumes in the Russian market. </P> |
| Havells India
Havells India
[07-Jul-2026] |
Havells India will hold a meeting of the Board of Directors of the Company on 17 July 2026. |
| Mid East Port.
Mid East Port.
[07-Jul-2026] |
Mid East Portfolio Management will hold a meeting of the Board of Directors of the Company on 9 July 2026. |
Old Backoffice
Data available till FY 2024-25 (Historical)
New Backoffice
Data From FY 2025-26 onwards (Latest)
